Sequence comparison
A'

PA (GETH) GENENTECH INC.
XX
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
DR WPI; 2000-072883/06.
DR P-PSDB; AAY66757.
XX
PT Membrane-bound proteins and related nucleotide sequences.
XX
PS Claim 2; Fig 289; 822pp; English.
XX
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences will
CC also be useful for the preparation of PRO polypeptides, especially by
CC recombinant techniques
XX
SQ Sequence 570 BP; 129 A; 190 C; 170 G; 81 T; 0 U; 0 Other;

Query Match 100.0%; Score 570; DB 3; Length 570;
Best Local Similarity 100.0%; Pred. No. 3.9e-89;
Matches 570; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GCGAGGACCGGGTATAAGAAGCCTCGTGGCCTTGCCCGGGCAGCCGCAGGTTCCCCGCGC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GCGAGGACCGGGTATAAGAAGCCTCGTGGCCTTGCCCGGGCAGCCGCAGGTTCCCCGCGC 60

Qy         61 GCCCCGAGCCCCCGCGCCATGAAGCTCGCCGCCCTCCTGGGGCTCTGCGTGGCCCTGTCC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GCCCCGAGCCCCCGCGCCATGAAGCTCGCCGCCCTCCTGGGGCTCTGCGTGGCCCTGTCC 120

Qy        121 TGCAGCTCCGCTGCTGCTTTCTTAGTGGGCTCGGCCAAGCCTGTGGCCCAGCCTGTCGCT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TGCAGCTCCGCTGCTGCTTTCTTAGTGGGCTCGGCCAAGCCTGTGGCCCAGCCTGTCGCT 180

Qy        181 GCGCTGGAGTCGGCGGCGGAGGCCGGGGCCGGGACCCTGGCCAACCCCCTCGGCACCCTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GCGCTGGAGTCGGCGGCGGAGGCCGGGGCCGGGACCCTGGCCAACCCCCTCGGCACCCTC 240

Qy        241 AACCCGCTGAAGCTCCTGCTGAGCAGCCTGGGCATCCCCGTGAACCACCTCATAGAGGGC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AACCCGCTGAAGCTCCTGCTGAGCAGCCTGGGCATCCCCGTGAACCACCTCATAGAGGGC 300

Qy        301 TCCCAGAAGTGTGTGGCTGAGCTGGGTCCCCAGGCCGTGGGGGCCGTGAAGGCCCTGAAG 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCCCAGAAGTGTGTGGCTGAGCTGGGTCCCCAGGCCGTGGGGGCCGTGAAGGCCCTGAAG 360
```

Sequence Comparison A

```
Qy      361 GCCCTGCTGGGGGCCCTGACAGTGTTTGGCTGAGCCGAGACTGGAGCATCTACACCTGAG 420
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      361 GCCCTGCTGGGGGCCCTGACAGTGTTTGGCTGAGCCGAGACTGGAGCATCTACACCTGAG 420

Qy      421 GACAAGACGCTGCCCACCCGCGAGGGCTGAAAACCCCGCCGCGGGGAGGACCGTCCATCC 480
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      421 GACAAGACGCTGCCCACCCGCGAGGGCTGAAAACCCCGCCGCGGGGAGGACCGTCCATCC 480

Qy      481 CCTTCCCCCGGCCCCTCTCAATAAACGTGGTTAAGAGCAAAAAAAAAAAAAAAAAAAAAA 540
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      481 CCTTCCCCCGGCCCCTCTCAATAAACGTGGTTAAGAGCAAAAAAAAAAAAAAAAAAAAAA 540

Qy      541 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 570
            ||||||||||||||||||||||||||||||
Db      541 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 570
```

Sequence Comparison 1B'

RESULT 2
AAY44458
ID AAY44458 standard; protein; 104 AA.
XX
AC AAY44458;
XX
DT 27-MAR-2000 (first entry)
XX
DE Human lung specific gene protein Lng107.
XX
KW Lung Specific Gene; LSG; Lng107; human; diagnostic marker; prognosticate;
KW lung cancer; diagnosis.
XX
OS Homo sapiens.
XX
PN WO9960160-A1.
XX
PD 25-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US010344.
XX
PR 21-MAY-1998; 98US-0086212P.
XX
PA (DIAD-) DIADEXUS LLC.
XX
PI Yang F, Macina RA, Sun Y;
XX
DR WPI; 2000-116320/10.
DR N-PSDB; AAZ29723.
XX
PT A new method for diagnosing, monitoring and staging lung cancer.
XX
PS Example 2; Page 38-39; 40pp; English.
XX
CC The present sequence is a lung specific gene (LSG) protein Lng107 from
CC human clone ID 586271. The LSG has high level of tissue specificity for
CC lungs and is overexpressed in cancerous tissues. The sequence serves as a
CC diagnostic marker for detecting, monitoring, staging and prognosticating
CC lung cancer. The diagnosis involves comparing levels of LSG in samples
CC obtained from patient and normal control
XX
SQ Sequence 104 AA;

  Query Match   100.0%; Score 502; DB 3; Length 104;
  Best Local Similarity   100.0%; Pred. No. 1.4e-48;
  Matches 104; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 MKLAALLGLCVALSCSSAAAFLVGSAKPVAQPVAALESAAEAGAGTLANPLGTLNPLKLL 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MKLAALLGLCVALSCSSAAAFLVGSAKPVAQPVAALESAAEAGAGTLANPLGTLNPLKLL 60

Qy         61 LSSLGIPVNHLIEGSQKCVAELGPQAVGAVKALKALLGALTVFG 104
              |||||||||||||||||||||||||||||||||||||||||||||
Db         61 LSSLGIPVNHLIEGSQKCVAELGPQAVGAVKALKALLGALTVFG 104
```

Sequence Comparison C'

PN WO200000610-A2.
XX
PD 06-JAN-2000.
XX
PF 25-JUN-1999; 99WO-US014484.
XX
PR 26-JUN-1998; 98US-0090762P.
PR 31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX
DR WPI; 2000-160673/14.
DR N-PSDB; AAZ98173.
XX
PT New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX
PS Claim 1; Page 206; 327pp; English.
XX
CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
CC used in gene therapy. HSPPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSPP. Antagonists of
CC HSPP are used to treat or prevent disorders associated with increased
CC activity or function of HSPP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
CC nucleic acids can be used for the recombinant production of HSPP, for
CC detecting HSPP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC or ribozyme therapeutics, for detecting related sequences or genetic
CC variations, and for chromosomal mapping. HSPP are also used to raise
CC specific antibodies (Ab) and to screen for agonists and antagonists
CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP
CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC competitive drug screens, and for purification of HSPP from natural
CC sources
XX
SQ Sequence 104 AA;

Query Match 100.0%; Score 502; DB 3; Length 104;
Best Local Similarity 100.0%; Pred. No. 1.4e-48;
Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Sequence Comparison C'